This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
Ord Minnett analyst maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh today and set a price target of A$38.35.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has an analyst consensus of Strong Buy, with a price target consensus of A$42.70.
Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of A$1.42 billion and a net profit of A$395.1 million. In comparison, last year the company earned a revenue of A$1.29 billion and had a net profit of A$365.04 million
Read More on AU:RMD:
Disclaimer & DisclosureReport an Issue
- ResMed General Counsel Trims Holdings to Cover RSU Tax Liability
- Early notable gainers among liquid option names on June 3rd
- ResMed Files 2025 Conflict Minerals Disclosure Under SEC Rules
- ResMed, Oura partner to expand access to sleep health education
- Analyst Maintains Hold on ResMed as Noctrix Acquisition Offers Limited Incremental Growth Amid Competitive Risks
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
